|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Reduction in the carrying amount of right-of-use assets | |||||
| Stock-based compensation | |||||
| Goodwill impairment | |||||
| Change in fair value of derivative liabilities | |||||
| Non-cash severance | |||||
| Change in deferred tax asset valuation allowance | |||||
| Accretion of discount on investments | |||||
| Other operating activities | |||||
| Changes in operating assets and liabilities: | |||||
| Other current and non-current assets | |||||
| Operating lease liabilities | |||||
| Other current and non-current liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of property and equipment | |||||
| Net cash acquired in acquisitions | |||||
| Other investing activities | |||||
| Purchases of investments | |||||
| Maturities and sales of investments | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of common stock | |||||
| Proceeds from issuance of Series U-2 preferred stock, net | |||||
| Payments for taxes on net settlement of equity incentive awards | |||||
| Other financing activities | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of the period | |||||
| Cash, cash equivalents, and restricted cash at end of the period | |||||
Loading...